Implant Sciences Corp. (OTCQB:IMSC) Wednesday reported another sale of its explosives trace detection system, this time to a major European airport.
The Quantum Sniffer QS-B220, launched in May 2011, is an explosives and drug trace detector that uses ion mobility to find trace amounts of narcotics and homemade bombs.
"Radiation concerns weigh heavily in the decision processes of European customers," Implant's Global VP of sales & marketing Darryl Jones said.
"Because our Quantum Sniffers do not use radioactive sources, they become a natural choice for European security equipment purchasers."
The European Union, late last year, banned the use of X-ray technology for security screening because of concerns about radiation risks.
Implant's chief executive, Glenn D. Bolduc, added: "Aviation security was a primary target when we developed the QS-B220."
"We are excited by the attention we are receiving in this important market, and look forward to the continued growth of the list of countries where the system is deployed."
The high-tech supplier of systems and sensors for homeland security markets said last week its QS-B220 explosives and drugs detector is being tested for air cargo screening by the U.S. Transportation Security Administration.
Implant Sciences also makes the Quantum Sniffer QS-H150, which is a trace detector that utilizes ion mobility spectrometry to find a number of military, commercial or homemade explosives.
The QS-H150 uses no radioactive materials and has a low-maintenance design.
Earlier this month, Implant reported new sales of its explosives trace detection system in Nigeria for aviation security.
The latest shipment went to ASL Airlines Services in Lagos, while implant's distributor A.C. Belgrave made the sale.
No comments:
Post a Comment